Literature DB >> 24916910

Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".

William N Whiteley1, Douglas Thompson2, Peter Sandercock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24916910      PMCID： PMC4282174          DOI： 10.1161/STROKEAHA.114.005871

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  2 in total

1.  Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".

Authors:  Qiliang Dai; Wen Sun; Xinfeng Liu
Journal:  Stroke       Date:  2014-06-10       Impact factor: 7.914

2.  Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.

Authors:  William N Whiteley; Douglas Thompson; Gordon Murray; Geoff Cohen; Richard I Lindley; Joanna Wardlaw; Peter Sandercock
Journal:  Stroke       Date:  2014-03-06       Impact factor: 7.914
  2 in total
  2 in total

1.  Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke.

Authors:  Min Li; Jing Zhou; Weifeng Jin; Xiaohong Li; Yuyan Zhang
Journal:  Front Pharmacol       Date:  2018-04-06       Impact factor: 5.810

2.  Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.

Authors:  Yan Li; Zi-Yu Zhu; Bing-Wei Lu; Ting-Ting Huang; Yue-Man Zhang; Na-Ying Zhou; Wei Xuan; Zeng-Ai Chen; Da-Xiang Wen; Wei-Feng Yu; Pei-Ying Li
Journal:  CNS Neurosci Ther       Date:  2019-11-22       Impact factor: 5.243
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.